Abstract:
:Bioavailability and therapeutic outcome of treatment with HIV-protease inhibitors depends on intestinal and hepatic transporter-enzyme interplay. Liver transport of HIV protease inhibitors (saquinavir, darunavir) was assessed in the presence of aged garlic extract, because the HIV-infected often consume garlic supplements together with prescribed therapy. The in vitro uptake of both drugs into HepG2 cells and precision cut rat liver slices significantly increased in the presence of Pgp and MRP-2 inhibitor ritonavir. The incubation medium containing aged garlic extract caused significant inhibition of saquinavir efflux from HepG2 cells and precision cut liver slices, while the activity of darunavir efflux transporters in both liver models significantly increased. Due to opposite in vitro interactions observed between aged garlic extract and HIV protease inhibitors, darunavir and saquinavir most probably bind to different binding sites on one or both efflux transporters. Based on this study, coadministration of investigated compounds with garlic supplements could result in significant in vivo modification of hepatic transport-enzyme interplay, possibly leading to further bioavailability change.
journal_name
Drug Metab Pharmacokinetjournal_title
Drug metabolism and pharmacokineticsauthors
Berginc K,Trontelj J,Kristl Adoi
10.2133/dmpk.25.307subject
Has Abstractpub_date
2010-01-01 00:00:00pages
307-13issue
3eissn
1347-4367issn
1880-0920pii
JST.JSTAGE/dmpk/25.307journal_volume
25pub_type
杂志文章abstract::Tralokinumab is a human monoclonal antibody in clinical development for asthma and atopic dermatitis that specifically neutralizes interleukin-13. This phase I, single-blind, randomized, placebo-controlled, single ascending-dose study assessed the safety, tolerability, pharmacokinetics (PK), and immunogenicity of subc...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章,随机对照试验
doi:10.1016/j.dmpk.2017.12.001
更新日期:2018-06-01 00:00:00
abstract::The objectives of this study were to develop a population pharmacokinetic model of imidafenacin and to explore the factors that affect the pharmacokinetics of imidafenecin. A total of 2406 plasma samples were collected from 90 healthy volunteers and 457 patients with overactive bladder. We determined the plasma concen...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.23.456
更新日期:2008-01-01 00:00:00
abstract::The present study was undertaken to characterize the transport of (3-methyl-His(2)) thyrotropin-releasing hormone ([(3)H]MeTRH) across the blood-brain barrier in mice and the effects of thyrotropin-releasing hormone (TRH) and its analogues (taltirelin and montirelin) on the transport and brain distribution. Integratio...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.18.310
更新日期:2003-01-01 00:00:00
abstract::Guanfacine hydrochloride extended-release tablet (GXR) is approved for child and adolescent patients with attention-deficit/hyperactivity disorder (ADHD). The aims of this study were to develop a population pharmacokinetic model of guanfacine after administration of GXR and to evaluate factors influencing the pharmaco...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2019.07.001
更新日期:2019-12-01 00:00:00
abstract::Clinical studies have revealed that some fluoroquinolones may cause severe adverse effects when co-administered with substrates of CYP1A2. Our previous study showed antofloxacin (ATFX) was responsible for mechanism-based inhibition (MBI) of the metabolism of phenacetin in rats. In the clinical setting, ATFX is likely ...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.dmpk-10-rg-126
更新日期:2011-01-01 00:00:00
abstract::Thirty-nine genetic variations, including thirty novel ones, were found in the human SLC29A1 gene, which encodes equilibrative nucleoside transporter 1, from 256 Japanese cancer patients administered gemcitabine. The found novel variations included -8,166G>A, -81,10A>G, -7,947G>A, -7,789T>C, -5,595G>A, -3,803_-3,783de...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.21.248
更新日期:2006-06-01 00:00:00
abstract:UNLABELLED:Better prediction of drug disposition prior to the clinical trial is critical for the efficient development of new drugs. The purpose of this study is to develop a novel multiple assessment methodology of hepatocellular drug disposition from drug uptake to efflux including biliary and basolateral excretion, ...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2015.12.001
更新日期:2016-04-01 00:00:00
abstract::The work described in this study aimed to express CYP2C8 wild-type and mutant proteins in bacterial expression system and to use the expressed proteins to investigate the structural and functional consequences of a reported allele CYP2C8(*)4 (carrying Ile264Met substitution) on protein activity. Ile264 was replaced by...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.23.165
更新日期:2008-01-01 00:00:00
abstract::Genetic polymorphisms in xenobiotic transporters have recently been clarified to be associated with change in drug distribution and disposition. To expand on recent identification of direct interaction and functional regulation of several transporters by a PDZ (PSD95, Dlg and ZO1) domain containing protein PDZK1, the ...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.21.375
更新日期:2006-10-01 00:00:00
abstract::Trimethylaminuria is caused by excessive malodorous trimethylamine excreted via urine and body secretion by decreased hepatic flavin-containing monooxygenase 3 (FMO3) metabolic capacity for transforming non-odorous trimethylamine N-oxide. This study investigates foodstuff first in healthy volunteers for palliative car...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.24.549
更新日期:2009-01-01 00:00:00
abstract::Cytochrome P450 (P450) constitutes a superfamily of enzymes which activate dioxygen and carry out monooxygenation reactions of large numbers of endogenous and xenobiotic compounds. Drug metabolism is a particularly important P450 function, and, therefore, elucidating the metabolic products and pathways of drugs is ess...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章,评审
doi:10.2133/dmpk.20.1
更新日期:2005-02-01 00:00:00
abstract::Tacrolimus is a widely used immunosuppressant after organ transplantation. The narrow therapeutic window and individual variability in tacrolimus pharmacokinetics make management of this agent a great challenge. This study was undertaken to determine the association of clinical markers, cytochrome P450, family 3, subf...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.dmpk-13-rg-095
更新日期:2014-01-01 00:00:00
abstract::Polymorphic distributions of pharmacogenes among some ethnicities are under-represented in current pharmacogenetic research. Particularly, there is a paucity of pharmacogenetic information in the Sherpa population in Tibet. We used the Sequenom MassARRAY single nucleotide polymorphism (SNP) genotyping technology to de...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2015.11.007
更新日期:2016-02-01 00:00:00
abstract::The present study aims is to investigate the metabolic mechanism of Xue-Fu-Zhu-Yu decoction (XFZYD) in the treatment of blood-stasis syndrome in Coronary Heart Disease (CHD). To that end, 30 CHD patients with Blood-Stasis Syndrome (BSS) and 20 healthy subjects were enrolled. LC-Q-TOF/MS analysis determined that in com...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2019.07.004
更新日期:2019-10-01 00:00:00
abstract::UDP-glucuronosyltransferases (UGTs) catalyze the glucuronidation of a wide variety of xeno/endobiotics. Previous studies have reported that human UGT enzymes are phosphorylated and that treatment of cells with protein kinase C (PKC) inhibitors results in decreased UGT activities without affecting the UGT protein level...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.DMPK-10-RG-121
更新日期:2011-06-01 00:00:00
abstract::We discovered a novel single nucleotide polymorphism (SNP) at position 325 (G325A) in exon 5 of the multidrug-resistance 1 (MDR1) gene in a study of 37 healthy Japanese subjects. Details are as follows. SNP, 020614Honda001; GENE NAME, human P-glycoprotein (MDR1); ACCESSION NUMBER, M29427; LENGTH, 25 bases; 5'-ATGAATCT...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.17.479
更新日期:2002-01-01 00:00:00
abstract::MCT1(SLC16A1) is the first member of the monocarboxylate transporter (MCT) and its family is involved in the transportation of metabolically important monocarboxylates such as lactate, pyruvate, acetate and ketone bodies. This study identifies genetic variations in SLC16A1 in the ethnic Chinese group of the Singaporea...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.24.469
更新日期:2009-01-01 00:00:00
abstract::We studied the intrahepatic disposition characteristics of galactosylated polyethylenimine (Gal-PEI)/plasmid DNA (pDNA) complexes using rat liver perfusion experiment. After intraportal administration, transfection activity in liver of Gal-PEI complexes was approximately 26-fold higher than that of native PEI complexe...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.18.230
更新日期:2003-01-01 00:00:00
abstract::1. Assay methods to detect drug interaction in toxicological samples were established by determining cytochrome P450 content and its activity in liver samples. The O-dealkylation reaction of 7-alkoxycoumarin was indicated to reflect changes in the molecular forms of P450s, and the enzyme induction or inhibition in the...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.17.379
更新日期:2002-01-01 00:00:00
abstract::In this study, we aimed to understand the gap in coverage of pharmacogenomic (PGx) biomarkers between Japan and the US. PGx biomarkers (1) in the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines; (2) that are CPIC level A or B; or (3) have US Food and Drug Administration (FDA)-approved drug labels...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2018.08.006
更新日期:2018-12-01 00:00:00
abstract::To evaluate the effect of protein binding of pilsicainide on its clearance and the contribution of protein binding to optimized pilsicainide therapy, clinical laboratory and pharmacokinetic data were studied in 160 Japanese inpatients (Study 1) and 18 Japanese inpatients (Study 2). To determine the relation between pr...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.20.183
更新日期:2005-06-01 00:00:00
abstract::The basement membrane at the blood-brain barrier (BBB) plays important roles in maintaining the structure and function of capillary vessels. The BBB is constructed from endothelial cells, astrocytes and pericytes, but their interactions in the formation or maintenance of basement membrane have not been established. Tr...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.22.255
更新日期:2007-08-01 00:00:00
abstract::Most of cytochrome P450 (CYP) expressions are regulated by nuclear receptors. The regulation pathways of transcription are activated by binding of the ligand to the receptor. Many combination of CYPs and nuclear receptors in transcriptional regulation have been reported. However, we have reported that the combination ...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2018.04.002
更新日期:2018-08-01 00:00:00
abstract::Since porphyrins are regarded as endogenous substrates for the ATP-binding cassette (ABC) transporter ABCG2, it is hypothesized that functional impairment owing to genetic polymorphisms or inhibition of ABCG2 by drugs may result in a disruption of cellular porphyrin homeostasis. In the present study, we expressed ABCG...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.22.428
更新日期:2007-12-01 00:00:00
abstract::After intravenous bolus administration of aprindine (AP) to conscious guinea pigs, the semilogarithmic plasma concentration versus time curve was linear at a dose of 2 mg/kg, but convex at doses of 5 and 10 mg/kg. AP concentrations immediately after administration (C(p0)) were almost identical, irrespective of the dos...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.17.292
更新日期:2002-01-01 00:00:00
abstract::The current EMA drug interaction guideline was published in 2012. This guideline gives important recommendations on the information required to elucidate the interaction potential of an investigational drug, both as effects of the investigational drug on the PK of other drugs and effects of other medicinal products on...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章,评审
doi:10.1016/j.dmpk.2019.11.005
更新日期:2020-02-01 00:00:00
abstract::In this study, a simple in vitro method for detecting human P450 (CYP) quasi-irreversible and irreversible inhibitors was evaluated. For the method, cDNA-expressed CYPs were applied to microtiter plate assays, CYP inhibitors were co-incubated with fluorometric substrates, and IC(50) were continuously measured (without...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.19.55
更新日期:2004-02-01 00:00:00
abstract::The hepatic uptake transporter organic anion transporting polypeptide (OATP) 1B1 is inhibited by some uremic toxins; however, direct inhibition can only partially explain the delayed systemic elimination of substrate drugs in renal failure patients. This study aimed to examine the long-lasting inhibition of OATP1B1 by...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2020.09.001
更新日期:2020-12-01 00:00:00
abstract::DDI could be caused by the inhibition of OATP-mediated hepatic uptakes. The aim of this study is to set the risk criteria for the compounds that would cause DDI via OATP inhibition at the drug discovery stage. The IC50 values of OATP inhibitors for human OATP-mediated atorvastatin uptake were evaluated in the expressi...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2016.05.003
更新日期:2016-10-01 00:00:00
abstract::It is now widely appreciated that drug metabolites, in addition to the parent drugs themselves, can mediate the serious adverse effects exhibited by some new therapeutic agents, and as a result, there has been heightened interest in the field of drug metabolism from researchers in academia, the pharmaceutical industry...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章,评审
doi:10.2133/dmpk.dmpk-10-rv-089
更新日期:2011-01-01 00:00:00